Stacie Jones
Concepts (419)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Food Hypersensitivity | 44 | 2024 | 98 | 10.790 |
Why?
| Peanut Hypersensitivity | 48 | 2024 | 85 | 8.690 |
Why?
| Desensitization, Immunologic | 46 | 2024 | 105 | 8.520 |
Why?
| Allergens | 52 | 2024 | 137 | 6.980 |
Why?
| Egg Hypersensitivity | 16 | 2021 | 26 | 2.470 |
Why?
| Anaphylaxis | 15 | 2024 | 71 | 2.260 |
Why?
| Immunoglobulin E | 29 | 2024 | 91 | 2.110 |
Why?
| Child | 77 | 2024 | 6849 | 1.780 |
Why?
| Administration, Oral | 35 | 2023 | 433 | 1.710 |
Why?
| Asthma | 11 | 2019 | 282 | 1.710 |
Why?
| Child, Preschool | 58 | 2024 | 3879 | 1.700 |
Why?
| Immune Tolerance | 16 | 2022 | 84 | 1.670 |
Why?
| Hypersensitivity | 4 | 2023 | 76 | 1.490 |
Why?
| Food Supply | 2 | 2023 | 91 | 1.420 |
Why?
| Immunotherapy | 10 | 2024 | 235 | 1.360 |
Why?
| Humans | 137 | 2024 | 49929 | 1.270 |
Why?
| Eosinophilic Esophagitis | 5 | 2024 | 39 | 1.250 |
Why?
| Adolescent | 48 | 2024 | 6417 | 1.230 |
Why?
| Epinephrine | 10 | 2022 | 97 | 1.050 |
Why?
| Double-Blind Method | 18 | 2023 | 679 | 0.960 |
Why?
| Nuts | 3 | 2022 | 8 | 0.900 |
Why?
| Patient Advocacy | 2 | 2013 | 15 | 0.860 |
Why?
| Skin Tests | 17 | 2019 | 55 | 0.850 |
Why?
| Male | 66 | 2024 | 25454 | 0.840 |
Why?
| Eosinophils | 4 | 2024 | 43 | 0.840 |
Why?
| Infant | 36 | 2024 | 3575 | 0.820 |
Why?
| Female | 65 | 2024 | 26576 | 0.790 |
Why?
| Health Education | 2 | 2013 | 153 | 0.780 |
Why?
| Allergy and Immunology | 3 | 2018 | 19 | 0.750 |
Why?
| Transdermal Patch | 2 | 2019 | 3 | 0.720 |
Why?
| Patient Education as Topic | 3 | 2017 | 315 | 0.720 |
Why?
| Esophagus | 2 | 2018 | 84 | 0.700 |
Why?
| Milk Hypersensitivity | 6 | 2024 | 19 | 0.660 |
Why?
| Treatment Outcome | 22 | 2024 | 5178 | 0.640 |
Why?
| School Nursing | 2 | 2010 | 9 | 0.630 |
Why?
| Arkansas | 13 | 2019 | 1990 | 0.580 |
Why?
| Egg Proteins | 6 | 2019 | 18 | 0.570 |
Why?
| Immunoglobulin G | 13 | 2022 | 184 | 0.560 |
Why?
| Health Literacy | 1 | 2019 | 130 | 0.560 |
Why?
| Sinusitis | 2 | 2007 | 42 | 0.540 |
Why?
| T-Lymphocytes, Regulatory | 5 | 2022 | 82 | 0.530 |
Why?
| National Institute of Allergy and Infectious Diseases (U.S.) | 12 | 2018 | 15 | 0.510 |
Why?
| Anti-Allergic Agents | 3 | 2024 | 16 | 0.490 |
Why?
| Plant Proteins | 6 | 2018 | 67 | 0.470 |
Why?
| Environmental Exposure | 4 | 2017 | 201 | 0.470 |
Why?
| Adult | 25 | 2024 | 13356 | 0.470 |
Why?
| Rural Population | 3 | 2018 | 549 | 0.450 |
Why?
| Risk Factors | 13 | 2019 | 3605 | 0.450 |
Why?
| Follow-Up Studies | 11 | 2021 | 2177 | 0.450 |
Why?
| Practice Guidelines as Topic | 6 | 2017 | 458 | 0.430 |
Why?
| Dermatitis, Atopic | 7 | 2016 | 39 | 0.420 |
Why?
| Basophils | 5 | 2018 | 15 | 0.420 |
Why?
| Receptors, Adrenergic, beta-2 | 4 | 2012 | 16 | 0.420 |
Why?
| Prevalence | 9 | 2019 | 956 | 0.410 |
Why?
| Poverty | 2 | 2012 | 207 | 0.410 |
Why?
| Young Adult | 15 | 2024 | 4031 | 0.390 |
Why?
| Gastrointestinal Tract | 2 | 2011 | 101 | 0.390 |
Why?
| Administration, Cutaneous | 5 | 2023 | 53 | 0.390 |
Why?
| Family | 1 | 2011 | 177 | 0.350 |
Why?
| Epidermal Growth Factor | 3 | 2005 | 33 | 0.350 |
Why?
| Parents | 2 | 2011 | 320 | 0.350 |
Why?
| Education, Nursing, Continuing | 1 | 2010 | 19 | 0.350 |
Why?
| Down-Regulation | 3 | 2012 | 342 | 0.350 |
Why?
| Cytokines | 6 | 2021 | 607 | 0.350 |
Why?
| Cross-Sectional Studies | 6 | 2019 | 1576 | 0.350 |
Why?
| Antibodies, Monoclonal | 2 | 2011 | 457 | 0.340 |
Why?
| United States | 22 | 2024 | 4883 | 0.340 |
Why?
| Nurse's Role | 1 | 2010 | 67 | 0.340 |
Why?
| Urban Population | 2 | 2010 | 151 | 0.330 |
Why?
| Mouth | 1 | 2009 | 31 | 0.320 |
Why?
| Clinical Competence | 3 | 2013 | 396 | 0.320 |
Why?
| Biomedical Research | 2 | 2018 | 241 | 0.310 |
Why?
| Rural Health | 1 | 2008 | 88 | 0.300 |
Why?
| Epitopes | 4 | 2022 | 59 | 0.300 |
Why?
| Air Pollution, Indoor | 1 | 2008 | 25 | 0.300 |
Why?
| Sympathomimetics | 3 | 2016 | 21 | 0.300 |
Why?
| Lung | 3 | 2019 | 501 | 0.290 |
Why?
| Adrenergic beta-Agonists | 3 | 2015 | 41 | 0.290 |
Why?
| CD4-Positive T-Lymphocytes | 2 | 2019 | 157 | 0.280 |
Why?
| Animals | 16 | 2024 | 13100 | 0.280 |
Why?
| Immunologic Factors | 3 | 2022 | 112 | 0.270 |
Why?
| Anti-Infective Agents | 1 | 2007 | 95 | 0.270 |
Why?
| Wound Healing | 2 | 2005 | 201 | 0.270 |
Why?
| Signal Transduction | 3 | 2005 | 1608 | 0.270 |
Why?
| Immunization | 5 | 2019 | 63 | 0.270 |
Why?
| Phenotype | 3 | 2018 | 728 | 0.270 |
Why?
| Case Management | 1 | 2006 | 42 | 0.270 |
Why?
| Cost of Illness | 1 | 2006 | 113 | 0.260 |
Why?
| Health Knowledge, Attitudes, Practice | 1 | 2010 | 488 | 0.260 |
Why?
| Population Surveillance | 1 | 2006 | 161 | 0.250 |
Why?
| Fear | 1 | 2006 | 84 | 0.250 |
Why?
| Administration, Sublingual | 4 | 2014 | 17 | 0.250 |
Why?
| Life Style | 1 | 2006 | 140 | 0.250 |
Why?
| Prospective Studies | 7 | 2020 | 2345 | 0.240 |
Why?
| Mycoses | 1 | 2006 | 158 | 0.240 |
Why?
| Severity of Illness Index | 5 | 2012 | 953 | 0.230 |
Why?
| Quality of Life | 2 | 2021 | 838 | 0.230 |
Why?
| Nutritional Status | 2 | 2023 | 136 | 0.230 |
Why?
| Body Mass Index | 1 | 2007 | 648 | 0.230 |
Why?
| Apoptosis | 1 | 2009 | 1092 | 0.220 |
Why?
| Medicine, Chinese Traditional | 2 | 2015 | 6 | 0.220 |
Why?
| Cell Movement | 1 | 2004 | 245 | 0.220 |
Why?
| Age Factors | 4 | 2020 | 1092 | 0.220 |
Why?
| Dietetics | 3 | 2017 | 11 | 0.220 |
Why?
| Agricultural Workers' Diseases | 1 | 2003 | 5 | 0.220 |
Why?
| Aircraft | 1 | 2003 | 9 | 0.220 |
Why?
| Leukocytes, Mononuclear | 4 | 2017 | 112 | 0.220 |
Why?
| Pesticides | 1 | 2003 | 18 | 0.210 |
Why?
| Antifungal Agents | 1 | 2006 | 343 | 0.210 |
Why?
| Candy | 1 | 2002 | 2 | 0.210 |
Why?
| Spirometry | 2 | 2018 | 30 | 0.200 |
Why?
| Th2 Cells | 2 | 2022 | 22 | 0.200 |
Why?
| T-Lymphocyte Subsets | 2 | 2023 | 38 | 0.200 |
Why?
| Diet | 2 | 2017 | 553 | 0.200 |
Why?
| Dust | 2 | 2014 | 22 | 0.200 |
Why?
| Antigens, Plant | 3 | 2020 | 14 | 0.200 |
Why?
| Occupational Exposure | 1 | 2003 | 112 | 0.190 |
Why?
| Middle Aged | 11 | 2024 | 12293 | 0.190 |
Why?
| Carbachol | 2 | 2019 | 27 | 0.190 |
Why?
| Longitudinal Studies | 3 | 2023 | 693 | 0.190 |
Why?
| Respiratory Hypersensitivity | 2 | 2019 | 17 | 0.190 |
Why?
| Toll-Like Receptor 8 | 1 | 2021 | 3 | 0.190 |
Why?
| Immunologic Deficiency Syndromes | 1 | 2021 | 19 | 0.190 |
Why?
| Mosaicism | 1 | 2021 | 18 | 0.190 |
Why?
| T-Lymphocytes | 3 | 2021 | 328 | 0.190 |
Why?
| Pancytopenia | 1 | 2021 | 36 | 0.180 |
Why?
| Health Promotion | 1 | 2023 | 264 | 0.180 |
Why?
| Clinical Trials as Topic | 3 | 2022 | 466 | 0.180 |
Why?
| Immunity, Mucosal | 2 | 2010 | 14 | 0.180 |
Why?
| Bronchodilator Agents | 2 | 2019 | 75 | 0.170 |
Why?
| Needs Assessment | 2 | 2010 | 133 | 0.170 |
Why?
| Tertiary Healthcare | 1 | 2019 | 16 | 0.160 |
Why?
| Isoproterenol | 2 | 2012 | 56 | 0.160 |
Why?
| Bronchoconstriction | 1 | 2019 | 6 | 0.160 |
Why?
| Hypersensitivity, Immediate | 3 | 2024 | 15 | 0.160 |
Why?
| Population Groups | 1 | 2018 | 6 | 0.160 |
Why?
| Acetazolamide | 1 | 2018 | 18 | 0.150 |
Why?
| Pseudotumor Cerebri | 1 | 2018 | 26 | 0.150 |
Why?
| Drug Hypersensitivity | 1 | 2018 | 37 | 0.150 |
Why?
| Cells, Cultured | 5 | 2015 | 1587 | 0.150 |
Why?
| Picornaviridae Infections | 1 | 2018 | 18 | 0.150 |
Why?
| Prognosis | 5 | 2021 | 1957 | 0.150 |
Why?
| Epithelial Cells | 3 | 2019 | 209 | 0.150 |
Why?
| Granulocytes | 1 | 2017 | 26 | 0.150 |
Why?
| Models, Biological | 2 | 2019 | 719 | 0.150 |
Why?
| Anticonvulsants | 1 | 2018 | 121 | 0.140 |
Why?
| Protein Transport | 2 | 2012 | 183 | 0.140 |
Why?
| Seasons | 1 | 2017 | 81 | 0.140 |
Why?
| Particulate Matter | 1 | 2017 | 54 | 0.140 |
Why?
| Inflammation | 1 | 2021 | 603 | 0.140 |
Why?
| Child Nutritional Physiological Phenomena | 1 | 2017 | 33 | 0.140 |
Why?
| Nut Hypersensitivity | 2 | 2015 | 3 | 0.140 |
Why?
| Proton Pump Inhibitors | 1 | 2017 | 85 | 0.140 |
Why?
| Primary Prevention | 1 | 2017 | 44 | 0.140 |
Why?
| Acetaminophen | 1 | 2019 | 275 | 0.130 |
Why?
| Respiratory Function Tests | 2 | 2008 | 88 | 0.130 |
Why?
| Evidence-Based Medicine | 1 | 2017 | 247 | 0.130 |
Why?
| Drugs, Chinese Herbal | 1 | 2015 | 5 | 0.130 |
Why?
| Basophil Degranulation Test | 1 | 2015 | 3 | 0.130 |
Why?
| Milk Proteins | 3 | 2024 | 77 | 0.120 |
Why?
| Therapies, Investigational | 1 | 2015 | 3 | 0.120 |
Why?
| Delivery of Health Care | 1 | 2018 | 308 | 0.120 |
Why?
| Cell Differentiation | 3 | 2021 | 649 | 0.120 |
Why?
| Microscopy, Fluorescence | 2 | 2008 | 164 | 0.120 |
Why?
| Guideline Adherence | 2 | 2016 | 134 | 0.120 |
Why?
| Patient Compliance | 1 | 2016 | 230 | 0.120 |
Why?
| Adrenal Cortex Hormones | 2 | 2024 | 99 | 0.120 |
Why?
| Randomized Controlled Trials as Topic | 3 | 2018 | 550 | 0.120 |
Why?
| Advisory Committees | 1 | 2014 | 61 | 0.120 |
Why?
| Meningitis, Pneumococcal | 1 | 2013 | 7 | 0.110 |
Why?
| Interleukin-1 Receptor-Associated Kinases | 1 | 2013 | 11 | 0.110 |
Why?
| Patient Selection | 1 | 2015 | 254 | 0.110 |
Why?
| Mycobacterium fortuitum | 1 | 2013 | 6 | 0.110 |
Why?
| Macrolides | 1 | 2013 | 16 | 0.110 |
Why?
| Manikins | 1 | 2013 | 35 | 0.110 |
Why?
| Immunoglobulins, Intravenous | 1 | 2013 | 55 | 0.110 |
Why?
| Plant Extracts | 1 | 2015 | 166 | 0.110 |
Why?
| Emergency Medicine | 1 | 2013 | 52 | 0.110 |
Why?
| Pediatrics | 2 | 2013 | 280 | 0.110 |
Why?
| Clarithromycin | 1 | 2013 | 38 | 0.110 |
Why?
| Sesamum | 1 | 2012 | 1 | 0.110 |
Why?
| Cohort Studies | 4 | 2020 | 1403 | 0.110 |
Why?
| Clindamycin | 1 | 2012 | 13 | 0.100 |
Why?
| Methicillin | 1 | 2012 | 11 | 0.100 |
Why?
| Research | 1 | 2013 | 107 | 0.100 |
Why?
| Medicaid | 2 | 2006 | 255 | 0.100 |
Why?
| House Calls | 1 | 2012 | 26 | 0.100 |
Why?
| Chickens | 2 | 2021 | 108 | 0.100 |
Why?
| Drug Resistance, Bacterial | 1 | 2012 | 72 | 0.100 |
Why?
| Gene Expression Profiling | 1 | 2016 | 1028 | 0.100 |
Why?
| Telemedicine | 1 | 2018 | 465 | 0.100 |
Why?
| Cyclic AMP | 3 | 2012 | 92 | 0.090 |
Why?
| Morbidity | 1 | 2012 | 128 | 0.090 |
Why?
| Influenza Vaccines | 1 | 2011 | 31 | 0.090 |
Why?
| Antibodies, Anti-Idiotypic | 1 | 2011 | 19 | 0.090 |
Why?
| Polymorphism, Genetic | 1 | 2012 | 181 | 0.090 |
Why?
| Powders | 2 | 2021 | 22 | 0.090 |
Why?
| Exercise | 1 | 2015 | 493 | 0.090 |
Why?
| Risk Assessment | 2 | 2017 | 1255 | 0.090 |
Why?
| Food | 1 | 2010 | 68 | 0.090 |
Why?
| Influenza, Human | 1 | 2011 | 83 | 0.090 |
Why?
| Child Nutrition Sciences | 1 | 2010 | 10 | 0.090 |
Why?
| Case-Control Studies | 2 | 2024 | 1129 | 0.090 |
Why?
| Specialization | 1 | 2010 | 46 | 0.090 |
Why?
| Clinical Protocols | 1 | 2010 | 109 | 0.090 |
Why?
| Retrospective Studies | 6 | 2016 | 6124 | 0.090 |
Why?
| Algorithms | 2 | 2020 | 613 | 0.090 |
Why?
| Maternal Exposure | 1 | 2010 | 89 | 0.090 |
Why?
| RNA, Ribosomal, 16S | 2 | 2023 | 111 | 0.090 |
Why?
| Caregivers | 1 | 2012 | 212 | 0.080 |
Why?
| Feces | 2 | 2023 | 131 | 0.080 |
Why?
| Nutrition Surveys | 1 | 2010 | 103 | 0.080 |
Why?
| Time Factors | 1 | 2016 | 2891 | 0.080 |
Why?
| Cooking | 2 | 2020 | 18 | 0.080 |
Why?
| Microarray Analysis | 1 | 2009 | 73 | 0.080 |
Why?
| Program Development | 1 | 2010 | 162 | 0.080 |
Why?
| Gene Expression | 2 | 2019 | 612 | 0.080 |
Why?
| Staphylococcal Infections | 1 | 2012 | 269 | 0.080 |
Why?
| Ovum | 2 | 2019 | 6 | 0.080 |
Why?
| Staphylococcus aureus | 1 | 2012 | 327 | 0.080 |
Why?
| Program Evaluation | 1 | 2010 | 349 | 0.080 |
Why?
| Respiratory Mechanics | 1 | 2008 | 41 | 0.080 |
Why?
| Anti-Asthmatic Agents | 2 | 2006 | 29 | 0.080 |
Why?
| Arachidonic Acid | 1 | 2008 | 34 | 0.080 |
Why?
| Recurrence | 2 | 2010 | 658 | 0.080 |
Why?
| Docosahexaenoic Acids | 1 | 2008 | 27 | 0.080 |
Why?
| 2S Albumins, Plant | 2 | 2020 | 7 | 0.080 |
Why?
| Statistics, Nonparametric | 1 | 2008 | 193 | 0.070 |
Why?
| Antibodies | 1 | 2008 | 151 | 0.070 |
Why?
| Health Surveys | 2 | 2012 | 234 | 0.070 |
Why?
| Meta-Analysis as Topic | 1 | 2007 | 38 | 0.070 |
Why?
| Luminescent Proteins | 2 | 2005 | 55 | 0.070 |
Why?
| Treatment Failure | 2 | 2020 | 116 | 0.070 |
Why?
| Health Status Indicators | 1 | 2007 | 83 | 0.070 |
Why?
| Infant, Newborn | 4 | 2019 | 2729 | 0.070 |
Why?
| Agammaglobulinemia | 1 | 2006 | 9 | 0.070 |
Why?
| Genetic Diseases, X-Linked | 1 | 2006 | 7 | 0.070 |
Why?
| Urban Health | 1 | 2006 | 30 | 0.070 |
Why?
| Infant Formula | 1 | 2008 | 145 | 0.070 |
Why?
| Acute Disease | 1 | 2007 | 367 | 0.070 |
Why?
| Anti-Bacterial Agents | 1 | 2012 | 742 | 0.070 |
Why?
| Nasal Polyps | 1 | 2006 | 4 | 0.070 |
Why?
| Consensus | 2 | 2017 | 155 | 0.070 |
Why?
| Amino Acids | 1 | 2008 | 363 | 0.060 |
Why?
| Bronchi | 1 | 2005 | 43 | 0.060 |
Why?
| Odds Ratio | 2 | 2019 | 548 | 0.060 |
Why?
| Antibody Specificity | 2 | 2017 | 35 | 0.060 |
Why?
| Recombinant Fusion Proteins | 2 | 2005 | 186 | 0.060 |
Why?
| Spine | 1 | 2006 | 91 | 0.060 |
Why?
| Predictive Value of Tests | 2 | 2020 | 907 | 0.060 |
Why?
| Pilot Projects | 1 | 2007 | 702 | 0.060 |
Why?
| Societies, Scientific | 2 | 2017 | 14 | 0.060 |
Why?
| Blood Proteins | 1 | 2004 | 77 | 0.060 |
Why?
| Osteoporosis | 1 | 2006 | 155 | 0.060 |
Why?
| Amino Acid Sequence | 2 | 2003 | 579 | 0.060 |
Why?
| Albuterol | 2 | 2019 | 56 | 0.060 |
Why?
| Tobacco Smoke Pollution | 1 | 2004 | 47 | 0.060 |
Why?
| Sex Factors | 1 | 2006 | 692 | 0.060 |
Why?
| Molecular Sequence Data | 2 | 2003 | 799 | 0.060 |
Why?
| Gene Transfer Techniques | 1 | 2003 | 38 | 0.060 |
Why?
| Adenoviridae | 1 | 2003 | 49 | 0.060 |
Why?
| Cattle | 1 | 2024 | 207 | 0.060 |
Why?
| Green Fluorescent Proteins | 1 | 2003 | 92 | 0.060 |
Why?
| Bone Density | 1 | 2006 | 383 | 0.060 |
Why?
| Butyrates | 1 | 2023 | 31 | 0.050 |
Why?
| Genetic Vectors | 1 | 2003 | 128 | 0.050 |
Why?
| Antigens | 1 | 2023 | 41 | 0.050 |
Why?
| Receptors, Vasopressin | 1 | 2003 | 23 | 0.050 |
Why?
| Inhalation Spacers | 1 | 2002 | 6 | 0.050 |
Why?
| Peak Expiratory Flow Rate | 1 | 2002 | 9 | 0.050 |
Why?
| Food Additives | 1 | 2002 | 7 | 0.050 |
Why?
| Gelatin | 1 | 2002 | 22 | 0.050 |
Why?
| Immunoglobulin A | 1 | 2022 | 45 | 0.050 |
Why?
| Metabolome | 1 | 2023 | 91 | 0.050 |
Why?
| Interleukin-2 | 1 | 2022 | 70 | 0.050 |
Why?
| Fibroblasts | 1 | 2004 | 352 | 0.050 |
Why?
| Pituitary Gland | 1 | 2003 | 85 | 0.050 |
Why?
| Protein Sorting Signals | 1 | 2002 | 10 | 0.050 |
Why?
| Recombinant Proteins | 1 | 2003 | 482 | 0.050 |
Why?
| Emollients | 1 | 2021 | 2 | 0.050 |
Why?
| Amino Acid Motifs | 1 | 2002 | 57 | 0.050 |
Why?
| Emergency Service, Hospital | 1 | 2006 | 487 | 0.050 |
Why?
| Socioeconomic Factors | 1 | 2004 | 584 | 0.050 |
Why?
| Ovomucin | 1 | 2021 | 1 | 0.050 |
Why?
| Vitellogenins | 1 | 2021 | 2 | 0.050 |
Why?
| Ovalbumin | 1 | 2021 | 18 | 0.050 |
Why?
| Genes, Reporter | 1 | 2002 | 89 | 0.050 |
Why?
| Sequence Alignment | 1 | 2002 | 121 | 0.050 |
Why?
| Endocytosis | 1 | 2002 | 61 | 0.050 |
Why?
| Hyperplasia | 1 | 2021 | 96 | 0.050 |
Why?
| Lysosomes | 1 | 2002 | 86 | 0.050 |
Why?
| Pedigree | 1 | 2021 | 125 | 0.050 |
Why?
| Injections, Subcutaneous | 1 | 2020 | 51 | 0.050 |
Why?
| Peptides | 1 | 2021 | 220 | 0.050 |
Why?
| Lymphocyte Activation | 1 | 2021 | 171 | 0.050 |
Why?
| Phylogeny | 2 | 2016 | 234 | 0.040 |
Why?
| B-Lymphocytes | 1 | 2021 | 175 | 0.040 |
Why?
| Milk | 2 | 2012 | 79 | 0.040 |
Why?
| Diet Therapy | 1 | 2019 | 8 | 0.040 |
Why?
| Kidney | 1 | 2004 | 672 | 0.040 |
Why?
| Immunity | 1 | 2019 | 34 | 0.040 |
Why?
| Age of Onset | 2 | 2012 | 108 | 0.040 |
Why?
| Tissue Array Analysis | 1 | 2019 | 45 | 0.040 |
Why?
| Cell Line | 1 | 2002 | 1010 | 0.040 |
Why?
| Egg Proteins, Dietary | 1 | 2018 | 2 | 0.040 |
Why?
| Muscle, Smooth | 1 | 2019 | 64 | 0.040 |
Why?
| Government Programs | 1 | 2018 | 16 | 0.040 |
Why?
| Organ Culture Techniques | 1 | 2019 | 48 | 0.040 |
Why?
| Dose-Response Relationship, Immunologic | 1 | 2018 | 13 | 0.040 |
Why?
| Gene Regulatory Networks | 1 | 2019 | 107 | 0.040 |
Why?
| Confidence Intervals | 1 | 2019 | 155 | 0.040 |
Why?
| ROC Curve | 1 | 2019 | 225 | 0.040 |
Why?
| Mice, Inbred Strains | 1 | 2019 | 160 | 0.040 |
Why?
| Extracellular Matrix | 1 | 2019 | 108 | 0.040 |
Why?
| Transforming Growth Factor beta | 1 | 2019 | 136 | 0.040 |
Why?
| Eating | 1 | 2019 | 157 | 0.040 |
Why?
| Rhinovirus | 1 | 2018 | 22 | 0.040 |
Why?
| Tertiary Care Centers | 1 | 2018 | 76 | 0.040 |
Why?
| Endoscopy | 1 | 2018 | 118 | 0.040 |
Why?
| Skin Irritancy Tests | 1 | 2017 | 3 | 0.040 |
Why?
| Gastrointestinal Diseases | 1 | 2018 | 128 | 0.040 |
Why?
| Transcriptome | 1 | 2019 | 312 | 0.040 |
Why?
| Blood Cells | 1 | 2017 | 43 | 0.040 |
Why?
| Multicenter Studies as Topic | 1 | 2017 | 89 | 0.040 |
Why?
| Specimen Handling | 1 | 2017 | 54 | 0.040 |
Why?
| Community Health Services | 1 | 2018 | 101 | 0.040 |
Why?
| Eczema | 1 | 2017 | 9 | 0.040 |
Why?
| Staining and Labeling | 1 | 2017 | 97 | 0.040 |
Why?
| Quality Assurance, Health Care | 1 | 2018 | 149 | 0.030 |
Why?
| Nutritional Sciences | 1 | 2017 | 30 | 0.030 |
Why?
| Molecular Sequence Annotation | 1 | 2016 | 27 | 0.030 |
Why?
| Disease Progression | 1 | 2019 | 820 | 0.030 |
Why?
| Histamine Antagonists | 1 | 2016 | 19 | 0.030 |
Why?
| Forkhead Transcription Factors | 1 | 2017 | 110 | 0.030 |
Why?
| Models, Statistical | 1 | 2018 | 225 | 0.030 |
Why?
| Risk Reduction Behavior | 1 | 2017 | 58 | 0.030 |
Why?
| Injections, Intramuscular | 1 | 2016 | 52 | 0.030 |
Why?
| Epigenesis, Genetic | 1 | 2019 | 370 | 0.030 |
Why?
| Quality Improvement | 1 | 2018 | 205 | 0.030 |
Why?
| Interleukin-5 | 1 | 2015 | 6 | 0.030 |
Why?
| Emergency Medical Services | 1 | 2016 | 110 | 0.030 |
Why?
| DNA Methylation | 1 | 2019 | 544 | 0.030 |
Why?
| Risk | 1 | 2016 | 314 | 0.030 |
Why?
| Cell Survival | 1 | 2017 | 590 | 0.030 |
Why?
| Dose-Response Relationship, Drug | 1 | 2019 | 1354 | 0.030 |
Why?
| Placebos | 1 | 2015 | 84 | 0.030 |
Why?
| Controlled Clinical Trials as Topic | 1 | 2015 | 21 | 0.030 |
Why?
| Interleukin-10 | 1 | 2015 | 83 | 0.030 |
Why?
| Flow Cytometry | 1 | 2017 | 470 | 0.030 |
Why?
| Housing | 1 | 2014 | 46 | 0.030 |
Why?
| Bacteria | 1 | 2016 | 219 | 0.030 |
Why?
| Oxidative Stress | 1 | 2019 | 759 | 0.030 |
Why?
| Medication Adherence | 1 | 2015 | 130 | 0.030 |
Why?
| Emergency Treatment | 1 | 2013 | 30 | 0.030 |
Why?
| Mice, Inbred C57BL | 1 | 2019 | 1777 | 0.030 |
Why?
| Antibiotic Prophylaxis | 1 | 2013 | 61 | 0.030 |
Why?
| Amikacin | 1 | 2013 | 19 | 0.030 |
Why?
| Azithromycin | 1 | 2013 | 25 | 0.030 |
Why?
| Glycoproteins | 1 | 2013 | 115 | 0.030 |
Why?
| Urticaria | 1 | 2013 | 18 | 0.030 |
Why?
| Antibody Affinity | 1 | 2012 | 7 | 0.030 |
Why?
| Incidence | 2 | 2006 | 986 | 0.030 |
Why?
| Comorbidity | 1 | 2015 | 610 | 0.030 |
Why?
| Trees | 1 | 2012 | 18 | 0.030 |
Why?
| Eggs | 1 | 2012 | 8 | 0.030 |
Why?
| Equipment Design | 1 | 2013 | 285 | 0.030 |
Why?
| Poisson Distribution | 1 | 2012 | 34 | 0.030 |
Why?
| Lysosomal-Associated Membrane Protein 1 | 1 | 2012 | 4 | 0.030 |
Why?
| Hospitals, University | 1 | 2012 | 77 | 0.020 |
Why?
| Rats | 2 | 2008 | 3273 | 0.020 |
Why?
| Patient Care Team | 1 | 2013 | 259 | 0.020 |
Why?
| rab GTP-Binding Proteins | 1 | 2012 | 37 | 0.020 |
Why?
| Protein Isoforms | 1 | 2012 | 118 | 0.020 |
Why?
| Membrane Proteins | 1 | 2013 | 347 | 0.020 |
Why?
| Regression Analysis | 1 | 2012 | 385 | 0.020 |
Why?
| HEK293 Cells | 1 | 2012 | 216 | 0.020 |
Why?
| Food Labeling | 1 | 2011 | 6 | 0.020 |
Why?
| Microbial Sensitivity Tests | 1 | 2012 | 271 | 0.020 |
Why?
| Hospitals, Pediatric | 1 | 2012 | 234 | 0.020 |
Why?
| Interleukin-4 | 1 | 2010 | 44 | 0.020 |
Why?
| Bronchitis | 1 | 2010 | 11 | 0.020 |
Why?
| Demography | 1 | 2010 | 93 | 0.020 |
Why?
| Intestinal Mucosa | 1 | 2011 | 215 | 0.020 |
Why?
| Diphenhydramine | 1 | 2009 | 20 | 0.020 |
Why?
| Antibodies, Monoclonal, Humanized | 1 | 2011 | 223 | 0.020 |
Why?
| Self Efficacy | 1 | 2010 | 130 | 0.020 |
Why?
| Oscillometry | 1 | 2008 | 9 | 0.020 |
Why?
| Fluorescent Antibody Technique, Indirect | 1 | 2008 | 19 | 0.020 |
Why?
| Infant Food | 1 | 2008 | 28 | 0.020 |
Why?
| Growth | 1 | 2008 | 40 | 0.020 |
Why?
| Internet | 1 | 2010 | 261 | 0.020 |
Why?
| Computer Simulation | 1 | 2008 | 281 | 0.020 |
Why?
| Intubation, Intratracheal | 1 | 2008 | 120 | 0.020 |
Why?
| Diagnosis, Differential | 1 | 2010 | 1037 | 0.020 |
Why?
| Reference Standards | 1 | 2006 | 52 | 0.020 |
Why?
| Administration, Inhalation | 1 | 2006 | 111 | 0.020 |
Why?
| Cause of Death | 1 | 2006 | 147 | 0.020 |
Why?
| Drug Combinations | 1 | 2005 | 126 | 0.020 |
Why?
| Absorptiometry, Photon | 1 | 2006 | 152 | 0.020 |
Why?
| Mitogen-Activated Protein Kinases | 1 | 2005 | 154 | 0.020 |
Why?
| Aged | 1 | 2018 | 9449 | 0.010 |
Why?
| Rats, Sprague-Dawley | 1 | 2008 | 1578 | 0.010 |
Why?
| Dietary Supplements | 1 | 2008 | 437 | 0.010 |
Why?
| Aging | 1 | 2008 | 669 | 0.010 |
Why?
| Sequence Homology | 1 | 2003 | 17 | 0.010 |
Why?
| Registries | 1 | 2006 | 523 | 0.010 |
Why?
| Second Messenger Systems | 1 | 2003 | 14 | 0.010 |
Why?
| Pregnancy | 1 | 2010 | 2468 | 0.010 |
Why?
| Phosphatidylinositols | 1 | 2003 | 27 | 0.010 |
Why?
| COS Cells | 1 | 2003 | 73 | 0.010 |
Why?
| Hydrophobic and Hydrophilic Interactions | 1 | 2003 | 35 | 0.010 |
Why?
| Durable Medical Equipment | 1 | 2002 | 2 | 0.010 |
Why?
| Cloning, Molecular | 1 | 2003 | 189 | 0.010 |
Why?
| Reimbursement Mechanisms | 1 | 2002 | 22 | 0.010 |
Why?
| Insurance, Pharmaceutical Services | 1 | 2002 | 25 | 0.010 |
Why?
| Bacterial Proteins | 1 | 2005 | 372 | 0.010 |
Why?
| Base Sequence | 1 | 2003 | 657 | 0.010 |
Why?
| Pharmacies | 1 | 2002 | 60 | 0.010 |
Why?
| Calcium | 1 | 2003 | 401 | 0.010 |
Why?
|
|
Jones's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|